journal article·2019-11-26Open access

Sulforaphane Mediates Glutathione Depletion via Polymeric Nanoparticles to Restore Cisplatin Chemosensitivity

Ying Xu, Xuexiang Han, Yiye Li, Huan Min, Xiao Zhao, Yinlong Zhang, Yingqiu Qi, Jian Shi, Sheng Qi, Yongping Bao, Guangjun Nie

ACS Nano· Volume 13· Issue 11

Abstract

Platinum (Pt)-based chemotherapy is a broadly used therapeutic regimen against various cancers. However, the insufficient cellular uptake, deactivation by thiol-containing species and nonspecific distribution of cisplatin (CDDP) result in its low chemosensitivity as well as systemic side effects, which can largely constrain the employment of CDDP in clinical treatment. To circumvent these problems, in this study, polymeric nanoparticles were utilized to codeliver a water-soluble CDDP derivative, poly(γ,l-glutamic acid)-CDDP conjugate, and a naturally occurring compound derived from broccoli, sulforaphane, which can achieve efficient glutathione (GSH) depletion, to improve the accumulation of CDDP in cancer cells. Results show that compared with combinational treatment of CDDP and SFN, the nanoparticles were more effectively internalized and could significantly reduce GSH content in breast cancer cells, leading to a notable increase in DNA-bound Pt and DNA damage-induced apoptosis. Moreover, in an orthotopic breast cancer model, the nanoparticles achieved a significantly higher tumor accumulation and exhibited a more powerful antitumor activity. Finally, this nanoenhanced chemotherapy was further confirmed in a liver cancer model with high-expression of GSH. Taken together, this sulforaphane-based nanostrategy holds great promise to enhance the sensitivity and therapeutic efficacy of Pt-based chemotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Chemotherapy-induced organ toxicity mitigation · Genomics, phytochemicals, and oxidative stress · Sulfur Compounds in Biology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, P.R. China

Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, P.R. China

Sino-Danish Center for Education and Research, Sino-Danish College of University of Chinese Academy of Sciences, Beijing 100049, P.R. China

Department of Chemistry, Tsinghua University, Beijing 100084, P.R. China

School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan, P.R. China

School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, U.K.

Norwich Medical School, University of East Anglia, Norwich, Norfolk NR4 7UQ, U.K.

Funding

Ministry of Science and Technology of the People's Republic of China · K. C. Wong Education Foundation · Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety · National Natural Science Foundation of China · Chinese Academy of Sciences · Cancer Prevention Research Trust

References (44)

Show source-provided references
1. 10.3322/caac.2155110.3322/caac.21551 ↗
2. 10.1200/JCO.2009.22.472510.1200/JCO.2009.22.4725 ↗
3. 10.1021/nn403606m10.1021/nn403606m ↗
4. 10.1021/acs.nanolett.8b0192410.1021/acs.nanolett.8b01924 ↗
5. 10.1038/nrc216710.1038/nrc2167 ↗
6. 10.1021/tx500112810.1021/tx5001128 ↗
7. 10.1038/sj.bjc.660277210.1038/sj.bjc.6602772 ↗
8. 10.1016/j.progpolymsci.2014.05.00210.1016/j.progpolymsci.2014.05.002 ↗
9. 10.1021/acsnano.5b0509710.1021/acsnano.5b05097 ↗
10. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
11. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
12. 10.1007/s11426-018-9397-510.1007/s11426-018-9397-5 ↗
13. Lee C. M. · Cancer Res. · 2002 · 62 · 4282
14. 10.1007/s00280005085510.1007/s002800050855 ↗
15. 10.1016/j.biomaterials.2006.08.01610.1016/j.biomaterials.2006.08.016 ↗
16. 10.1016/j.biomaterials.2012.06.07110.1016/j.biomaterials.2012.06.071 ↗
17. 10.1023/A:101090891618410.1023/A:1010908916184 ↗
18. Nishiyama N. · Cancer Res. · 2003 · 63 · 8977
19. 10.1016/j.jconrel.2016.02.03910.1016/j.jconrel.2016.02.039 ↗
20. 10.1038/bjc.2011.610.1038/bjc.2011.6 ↗
21. 10.1007/s00280-011-1572-510.1007/s00280-011-1572-5 ↗
22. 10.1038/onc.2011.38410.1038/onc.2011.384 ↗
23. 10.1038/cddis.2013.42810.1038/cddis.2013.428 ↗
24. 10.1006/bbrc.1995.261810.1006/bbrc.1995.2618 ↗
25. 10.1016/j.bcp.2005.03.01510.1016/j.bcp.2005.03.015 ↗
26. 10.1016/j.canlet.2008.04.01810.1016/j.canlet.2008.04.018 ↗
27. 10.1016/j.jnutbio.2007.02.01410.1016/j.jnutbio.2007.02.014 ↗
28. 10.1158/0008-5472.CAN-07-617110.1158/0008-5472.CAN-07-6171 ↗
29. 10.1208/s12248-009-9162-810.1208/s12248-009-9162-8 ↗
30. 10.1097/00001813-200204000-0000110.1097/00001813-200204000-00001 ↗
31. 10.1371/journal.pone.013877110.1371/journal.pone.0138771 ↗
32. 10.1016/j.biomaterials.2011.07.03210.1016/j.biomaterials.2011.07.032 ↗
33. 10.1080/1071754070120293710.1080/10717540701202937 ↗
34. 10.1111/j.1349-7006.2010.01708.x10.1111/j.1349-7006.2010.01708.x ↗
35. 10.1002/adfm.20140158310.1002/adfm.201401583 ↗
36. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
37. 10.1016/j.nantod.2016.04.00810.1016/j.nantod.2016.04.008 ↗
38. 10.1016/j.biomaterials.2016.06.03210.1016/j.biomaterials.2016.06.032 ↗
39. 10.1002/adma.20120475010.1002/adma.201204750 ↗
40. 10.1016/S0140-6736(95)91693-810.1016/S0140-6736(95)91693-8 ↗
41. 10.1158/1535-7163.MCT-06-049410.1158/1535-7163.MCT-06-0494 ↗
42. 10.3109/13880209.2012.76124210.3109/13880209.2012.761242 ↗
43. 10.1002/adma.20180121610.1002/adma.201801216 ↗
44. Syng-Ai C. · Mol. Cancer Ther. · 2004 · 3 · 110110.1158/1535-7163.1101.3.9 ↗